Acute kidney injury risk with SGLT2 inhibitors versus sulfonylureas by baseline cardiorenal status in type 2 diabetes: A nationwide cohort study
In a large nationwide Korean cohort study, initiating SGLT2 inhibitors as second-line therapy for type 2 diabetes was associated with a significantly lower 180-day risk of acute kidney injury compared to sulfonylureas, a protective effect that persisted in patients with heart failure but was attenuated among those with pre-existing chronic kidney disease.